Modakafusp alfa
- Generic Name
- Modakafusp alfa
- Drug Type
- Biotech
- Unique Ingredient Identifier
- TN8CEX4UT2
- Background
Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)).
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 58
- Registration Number
- NCT05590377
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division), Overland Park, Kansas, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT04392648
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT04157517
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Cotton Cancer Center Lebanon, Lebanon, New Hampshire, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 272
- Registration Number
- NCT03215030
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.